[1] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[2] |
YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin.
Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
|
[3] |
ZHU Yuanchao, ZHANG Yatong, HU Xin.
Principles and measures of medication risk management in the elderly
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.
|
[4] |
SONG Mingyue, ZHANG Ran, WU Zhiang.
Influencing factors of quality risk management of drug recall in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1087-1090.
|
[5] |
ZHENG Mingjie, ChENG Rong, SONG Haibo.
Bibliometric Analysis of Pharmacovigilance Research in China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 686-688.
|
[6] |
FAN Yan, WANG Dan, WANG Chunting.
The Mechanism of Toxicity Reaction Induced by Protamine Sulfate Injection
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1159-1161.
|
[7] |
XUE Wei, QI Wenyuan, LIU Yue, CONG Duanduan, LIU Xiaohui, LI Hongyan, WANG Juan, LI Kexin, HU Xin.
Design and Implementation of Bioequivalence Tests Based on Risk Management Strategies
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 549-552.
|
[8] |
YANG Yue.
Implementation of Pharmacovigilance System in Drug Administration Law and Application of ICH E2 Guideline
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 65-71.
|
[9] |
WEI Fuqian, ZHANG Wei, YANG Yue.
Implementation of US FDA's Drug Risk Evaluation and Mitigation Strategies
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 871-876.
|
[10] |
ZHANG Rui, PAN Yan, WU Zhiang.
Quality Risk Management during Implementation of Phase Ⅱa Clinical Trials of Innovative Anti-tumor Drugs
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 886-889.
|
[11] |
ZOU Limin, QI Yueli, TANG Ling, DU Yu, YANG Zhimin.
How to Develop a Post-marketing Risk Management Plan for New Drug Applications in Line with E2E Guidelines
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 780-784.
|
[12] |
SANG Yuan, WU Shifu, LU Changfei, XIE Yanjun, CUI Xiaokang, XU Lili, LIU Wenwen, HUO Yanfei.
Problems and Thoughts on Reporting and Monitoring of Adverse Drug Reactions in Drug Manufacturers
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 215-218.
|
[13] |
ZOU Limin, QI Yueli, TANG Ling, YANG Zhimin.
Post-marketing Risk Management of New Drugs in China Inspired by E2E Guidelines
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 670-674.
|
[14] |
DING Faming, ZHANG Xinli, WANG Qiong, YIN Maoshan.
Preliminary Discussion on the Risk Management of QT-prolonging Drugs Use and Its Implication
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(9): 545-549.
|
[15] |
Endocrinology and Metabolism Branch of Chinese Association of Geriatric Research, Committee of Clinical Toxicology of Chinese Society of Toxicology.
Expert Consensus on Risk Management of Polypharmacy in Elderly
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(10): 627-640.
|